IVVD
Invivyd, Inc. NASDAQ Listed Aug 6, 2021$1.44
Mkt Cap $190.5M
52w Low $0.48
36.8% of range
52w High $3.07
50d MA $1.56
200d MA $1.65
P/E (TTM)
-5.1x
EV/EBITDA
-3.8x
P/B
1.1x
Debt/Equity
0.0x
ROE
-21.7%
P/FCF
-7.3x
RSI (14)
—
ATR (14)
—
Beta
0.74
50d MA
$1.56
200d MA
$1.65
Avg Volume
2.8M
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
1601 Trapelo Road · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 1.46 | +2.7% | -2.1% | — | — | — | — | — |
| Mar 5, 2026 | AMC | -0.06 | 0.02 | +133.3% | 1.74 | -2.3% | +3.4% | +5.0% | -3.2% | +3.8% | -5.3% | — |
| Nov 6, 2025 | AMC | -0.05 | -0.06 | -20.0% | 1.54 | -3.9% | +3.2% | +1.3% | +2.5% | +7.3% | +0.0% | — |
| Aug 14, 2025 | AMC | -0.04 | -0.12 | -200.0% | 0.80 | -10.3% | -11.5% | -17.8% | -1.7% | +11.0% | -16.7% | — |
| May 15, 2025 | AMC | -0.04 | -0.14 | -250.0% | 0.70 | -0.3% | +10.3% | -0.1% | +4.3% | -5.5% | -0.5% | — |
| Mar 20, 2025 | AMC | -0.25 | -0.15 | +40.0% | 0.74 | +3.3% | -0.1% | -1.9% | -8.9% | -6.7% | -0.9% | — |
| Nov 14, 2024 | AMC | -0.33 | -0.51 | -54.5% | 0.79 | +3.7% | -4.5% | -2.0% | +3.7% | +0.1% | -8.9% | — |
| Aug 14, 2024 | AMC | -0.37 | -0.40 | -8.1% | 0.98 | +0.0% | +6.1% | -6.1% | -6.5% | -5.5% | +1.7% | — |
| May 9, 2024 | AMC | -0.51 | -0.38 | +25.5% | 2.42 | -0.8% | -6.6% | +4.9% | +2.5% | +1.2% | -0.4% | — |
| Mar 28, 2024 | AMC | -0.41 | -0.67 | -63.4% | 4.44 | +5.9% | -4.3% | -10.4% | +3.1% | -8.9% | -7.8% | — |
| Nov 9, 2023 | AMC | -0.54 | -0.36 | +33.3% | 1.40 | +2.1% | +0.0% | +7.1% | +0.0% | -1.3% | +1.4% | — |
| Aug 10, 2023 | AMC | -0.40 | -0.46 | -15.0% | 1.55 | +3.2% | +3.2% | +0.0% | +2.5% | +1.2% | +3.0% | — |
| May 11, 2023 | AMC | -0.36 | -0.32 | +11.1% | 1.43 | +0.0% | +0.7% | +6.2% | -2.0% | +1.3% | -17.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $1.71 | $1.73 | +1.2% | -0.6% | -0.6% | +1.8% | -5.8% | +5.6% |
| Dec 23 | BTIG | Maintains | Buy → Buy | — | $2.88 | $2.90 | +0.7% | -2.8% | +0.4% | -4.3% | -3.7% | -6.2% |
| Nov 25 | D. Boral Capital | Downgrade | Buy → Hold | — | $2.40 | $2.34 | -2.5% | -5.4% | +2.6% | +4.3% | +2.9% | -13.6% |
| Nov 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.76 | $1.80 | +2.3% | -8.5% | -13.0% | +8.6% | +1.3% | +3.2% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.87 | $1.86 | -0.5% | -5.9% | -8.5% | -13.0% | +8.6% | +1.3% |
| Oct 6 | D. Boral Capital | Maintains | Buy → Buy | — | $1.16 | $1.29 | +11.2% | +22.4% | +14.8% | +0.6% | +15.2% | -6.9% |
| Aug 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.03 | $1.02 | -1.0% | -15.4% | +13.7% | -1.7% | +5.9% | +1.0% |
| Aug 25 | D. Boral Capital | Maintains | Buy → Buy | — | $0.52 | $0.53 | +2.6% | +7.6% | +84.0% | -15.4% | +13.7% | -1.7% |
| Aug 19 | D. Boral Capital | Maintains | Buy → Buy | — | $0.58 | $0.59 | +2.4% | -1.7% | +11.0% | -16.7% | -1.5% | +7.6% |
| Aug 15 | D. Boral Capital | Maintains | Buy → Buy | — | $0.80 | $0.72 | -10.3% | -11.5% | -17.8% | -1.7% | +11.0% | -16.7% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.70 | $0.73 | +4.2% | +13.4% | -9.1% | -1.6% | +0.9% | +0.2% |
| Jun 26 | D. Boral Capital | Maintains | Buy → Buy | — | $0.70 | $0.73 | +4.2% | +13.4% | -9.1% | -1.6% | +0.9% | +0.2% |
| May 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.90 | $0.89 | -1.0% | -6.0% | +0.2% | +10.3% | -0.5% | +3.9% |
| May 16 | D. Boral Capital | Maintains | Buy → Buy | — | $0.70 | $0.70 | -0.3% | +10.3% | -0.1% | +4.3% | -5.5% | -0.5% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.66 | $0.67 | +1.6% | -6.7% | -0.9% | -1.6% | +0.9% | -10.8% |
| Mar 20 | D. Boral Capital | Maintains | Buy → Buy | — | $0.72 | $0.72 | +0.4% | +2.6% | -0.1% | -1.9% | -8.9% | -6.7% |
| Mar 5 | D. Boral Capital | Maintains | Buy → Buy | — | $1.05 | $1.15 | +9.5% | +1.0% | -2.8% | -1.9% | -9.4% | -7.5% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.77 | $1.30 | -26.6% | -29.9% | +4.8% | -5.4% | +0.8% | -6.5% |
| Feb 24 | D. Boral Capital | Maintains | Buy → Buy | — | $1.77 | $1.30 | -26.6% | -29.9% | +4.8% | -5.4% | +0.8% | -6.5% |
| Feb 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.26 | +18.9% | +17.9% | +68.8% | -6.2% | +3.0% | -23.0% |
| Feb 3 | D. Boral Capital | Maintains | Buy → Buy | — | $0.36 | $0.44 | +24.2% | +196.3% | +17.9% | +68.8% | -6.2% | +3.0% |
| Jan 27 | D. Boral Capital | Maintains | Buy → Buy | — | $0.47 | $0.46 | -2.2% | -12.9% | +0.4% | -6.9% | +1.2% | -8.3% |
| Jan 10 | D. Boral Capital | Maintains | Buy → Buy | — | $0.46 | $0.46 | -0.3% | -2.1% | -11.7% | +1.4% | +2.1% | +6.3% |
| Nov 21 | D. Boral Capital | Maintains | Buy → Buy | — | $0.77 | $0.76 | -0.6% | -8.9% | +0.2% | -4.4% | -12.0% | +14.3% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.77 | $0.76 | -0.5% | +0.1% | -8.9% | +0.2% | -4.4% | -12.0% |
| Nov 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $0.77 | $0.76 | -0.5% | +0.1% | -8.9% | +0.2% | -4.4% | -12.0% |
| Nov 14 | D. Boral Capital | Maintains | Buy → Buy | — | $0.89 | $0.89 | +0.0% | -11.2% | -4.5% | -2.0% | +3.7% | +0.1% |
| Oct 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.04 | $1.01 | -2.9% | -12.8% | +0.4% | -1.9% | +2.4% | -1.6% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.85 | $0.86 | +1.2% | +0.2% | -0.2% | +0.2% | -4.4% | +10.7% |
| Aug 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.88 | $0.90 | +1.9% | -3.8% | +0.2% | -0.2% | +0.2% | -4.4% |
| Aug 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.29 | $1.29 | +0.0% | -28.7% | -2.2% | -1.8% | -3.8% | +0.2% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.01 | $2.00 | -0.5% | -4.0% | -8.8% | -4.5% | +7.7% | +1.7% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.37 | $2.37 | +0.0% | +2.5% | +1.2% | -0.4% | -2.0% | -6.2% |
| Apr 5 | Guggenheim | Upgrade | Neutral → Buy | — | $3.58 | $3.77 | +5.3% | -7.8% | -7.3% | -1.3% | -0.3% | +1.7% |
| Mar 26 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $3.23 | $3.87 | +19.8% | +13.3% | +9.3% | +11.0% | -4.3% | -10.4% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.36 | $4.02 | -7.8% | -25.9% | +13.3% | +9.3% | +11.0% | -4.3% |
| Jan 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.12 | $4.51 | +9.5% | +7.8% | +5.9% | -4.3% | -0.9% | -0.7% |
| Dec 19 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $3.59 | $2.96 | -17.5% | -7.5% | +2.7% | +10.0% | +3.5% | -5.9% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.60 | $1.56 | -2.5% | +0.0% | +2.5% | +1.2% | +3.0% | -8.2% |
| Jul 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.41 | +1.4% | -1.4% | -1.5% | +7.4% | +0.7% | -4.1% |
| Jun 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.03 | -2.8% | +0.9% | -1.9% | +6.7% | +6.2% | -5.0% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.44 | $1.45 | +0.7% | +6.2% | -2.0% | +1.3% | -17.8% | -0.8% |
| Mar 27 | Morgan Stanley | Maintains | Underweight → Underweight | — | $1.31 | $1.28 | -2.3% | +6.5% | -3.2% | -4.4% | -8.1% | +1.3% |
| Jan 24 | Morgan Stanley | Maintains | Underweight → Underweight | — | $2.04 | $2.02 | -1.0% | +7.8% | +10.0% | -1.2% | +3.8% | -8.5% |
| Sep 16 | Morgan Stanley | Maintains | Underweight → Underweight | — | $4.07 | $4.02 | -1.2% | -5.7% | -7.0% | -3.6% | -4.4% | -0.6% |
| Sep 14 | Morgan Stanley | Maintains | Underweight → Underweight | — | $4.83 | $4.65 | -3.7% | -9.3% | -7.1% | -5.7% | -7.0% | -3.6% |
| May 16 | Morgan Stanley | Maintains | Underweight → Underweight | — | $2.72 | $2.74 | +0.7% | +5.5% | +6.6% | -3.6% | +0.7% | -0.7% |
| Jan 5 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $7.22 | $6.96 | -3.6% | -10.0% | -5.8% | -3.1% | +3.0% | -1.5% |
| Dec 21 | Jefferies | Downgrade | Buy → Hold | — | $10.00 | $9.65 | -3.5% | +2.9% | -13.4% | -2.8% | +3.9% | -12.8% |
| Dec 14 | Guggenheim | Downgrade | Buy → Neutral | — | $34.26 | $10.00 | -70.8% | -78.8% | -12.5% | +123.3% | -19.0% | -12.9% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Invivyd's pipeline expansion with a potential first-in-class measles antibody and clinical progress on COVID-19 candidate could justify premium valuation if development succeeds, but investors should monitor clinical trial results carefully.
Apr 9
8-K · 8.01
!! High
Invivyd, Inc. -- 8-K 8.01: Material Event / Announcement
Invivyd updated its corporate presentation on March 5, 2026, providing investors with current information about the company's business strategy and operations.
Mar 5
Data updated apr 25, 2026 4:32pm
· Source: massive.com